Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.79 |
| ▸ | CCND1 | P24385 | 18/20 | 0.79 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.79 |
| ▸ | CCND3 | P30281 | 7/20 | 0.79 |
| ▸ | CDK2 | P24941 | 4/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.79 |
| ▸ | FECH | P22830 | 1/20 | 0.79 |
| ▸ | CDK9 | P50750 | 1/20 | 0.79 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.79 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.79 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.79 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.79 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.79 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.79 |
| ▸ | CDK1 | P06493 | 1/20 | 0.76 |
| ▸ | CCND2 | P30279 | 6/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23837859 | 0.91 | CDK4 (0.83) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL2685016 | 0.90 | CDK4 (0.81) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507453 | 0.90 | CDK4 (0.81) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL31121782 | 0.89 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL303542 | 0.89 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| Dimethylamine SCHEMBL28726027 | 0.89 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507623 | 0.89 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL302310 | 0.88 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL29384231 | 0.88 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL29385337 | 0.88 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090306-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | G1 THERAPEUTICS, INC. | 2021-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090306-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | CDK4 2/4885CCND1 85/4885CDK6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.